Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,536 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT02227108 | Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma | terminated | Phase 2 | 37 | MedImmune LLCINDUSTRY | 8 | Apr 6, 2017 | clinicaltrials |
| NCT00738699 | An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer(FAR-122) | terminated | Phase 2 | 415 | MorphotekINDUSTRY | 6 | Mar 30, 2017 | clinicaltrials |
| NCT00244764 | GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma | completed | Phase 2 | 225 | GlaxoSmithKlineINDUSTRY | 8 | Mar 27, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT01289821 | First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib | completed | Phase 2 | 54 | BayerINDUSTRY | 7 | Mar 15, 2017 | clinicaltrials |
| NCT01572727 | A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation(BELLE-4) | completed | Phase 2 / Phase 3 | 416 | Novartis PharmaceuticalsINDUSTRY | 22 | Mar 9, 2017 | clinicaltrials |
| NCT01744691 | A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion | completed | Phase 2 | 145 | Pharmacyclics LLC.INDUSTRY | 9 | Feb 27, 2017 | clinicaltrials |
| NCT00171912 | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | completed | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00880269 | Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 23, 2017 | clinicaltrials |
| NCT00193973 | Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma | completed | Phase 2 | 20 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Feb 17, 2017 | clinicaltrials |
| NCT00358956 | A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer | completed | Phase 2 | 19 | Genzyme, a Sanofi CompanyINDUSTRY | 8 | Jan 30, 2017 | clinicaltrials |
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma(COMMAND) | terminated | Phase 2 | 344 | Verastem, Inc.INDUSTRY | 15 | Jan 30, 2017 | clinicaltrials |
| NCT00873093 | Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | completed | Phase 2 | 148 | National Cancer Institute (NCI)NIH | 4 | Jan 27, 2017 | clinicaltrials |
| NCT00256880 | Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma | completed | Phase 2 | 100 | GlaxoSmithKlineINDUSTRY | 2 | Jan 18, 2017 | clinicaltrials |
| NCT01820364 | LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma(LOGIC) | terminated | Phase 2 | 15 | Array BioPharmaINDUSTRY | 6 | Jan 9, 2017 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT01521143 | Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment(CANVAS) | terminated | Phase 2 | 91 | Prima BioMed LtdINDUSTRY | 2 | Dec 14, 2016 | clinicaltrials |
| NCT02748213 | A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | completed | Phase 2 | 225 | Hoffmann-La RocheINDUSTRY | 15 | Nov 22, 2016 | clinicaltrials |
| NCT00903175 | Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma(RECORD-3) | completed | Phase 2 | 471 | Novartis PharmaceuticalsINDUSTRY | 19 | Nov 8, 2016 | clinicaltrials |
| NCT01087151 | A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 118 | Genentech, Inc.INDUSTRY | 12 | Nov 2, 2016 | clinicaltrials |
| NCT01437566 | Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy | completed | Phase 2 | 318 | Genentech, Inc.INDUSTRY | 23 | Nov 2, 2016 | clinicaltrials |
| NCT01577173 | A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck | completed | Phase 2 | 122 | Genentech, Inc.INDUSTRY | 11 | Nov 2, 2016 | clinicaltrials |
| NCT01652482 | Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) | completed | Phase 2 | 135 | Genentech, Inc.INDUSTRY | 10 | Nov 2, 2016 | clinicaltrials |
| NCT02147873 | Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL | terminated | Phase 2 | 118 | TetraLogic PharmaceuticalsINDUSTRY | 4 | Oct 20, 2016 | clinicaltrials |
| NCT01617668 | A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer | completed | Phase 2 | 209 | Novartis PharmaceuticalsINDUSTRY | 12 | Oct 17, 2016 | clinicaltrials |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | BayerINDUSTRY | 11 | Oct 7, 2016 | clinicaltrials |
| NCT01777776 | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | terminated | Phase 1 / Phase 2 | 28 | Array BioPharmaINDUSTRY | 4 | Sep 13, 2016 | clinicaltrials |
| NCT01964235 | Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 7 | Sep 1, 2016 | clinicaltrials |
| NCT01826214 | Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia | completed | Phase 2 | 70 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 30, 2016 | clinicaltrials |
| NCT01399684 | A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer | completed | Phase 2 | 127 | Genentech, Inc.INDUSTRY | 5 | Aug 26, 2016 | clinicaltrials |
| NCT00404703 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer | terminated | Phase 2 | 37 | Hoffmann-La RocheINDUSTRY | 10 | Aug 24, 2016 | clinicaltrials |
| NCT00327535 | A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy. | completed | Phase 2 | 153 | Hoffmann-La RocheINDUSTRY | 15 | Aug 11, 2016 | clinicaltrials |
| NCT01590719 | A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer | completed | Phase 2 | 123 | Hoffmann-La RocheINDUSTRY | 6 | Aug 9, 2016 | clinicaltrials |
| NCT00454805 | AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. | completed | Phase 2 | 75 | AstraZenecaINDUSTRY | 3 | Aug 3, 2016 | clinicaltrials |
| NCT00958841 | Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin | terminated | Phase 2 | 118 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 26, 2016 | clinicaltrials |
| NCT00079482 | Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) | completed | Phase 2 | 224 | CephalonINDUSTRY | 13 | Jul 21, 2016 | clinicaltrials |
| NCT01325428 | Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer | completed | Phase 2 | 26 | Boehringer IngelheimINDUSTRY | 7 | Jul 19, 2016 | clinicaltrials |
| NCT02063295 | An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury | completed | Phase 2 | 14 | Zafgen, Inc.INDUSTRY | 2 | Jul 18, 2016 | clinicaltrials |
| NCT00002624 | Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function | completed | Phase 2 | 66 | Alliance for Clinical Trials in OncologyOTHER | 4 | Jul 14, 2016 | clinicaltrials |
| NCT00091377 | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 65 | MEI Pharma, Inc.INDUSTRY | 2 | Jul 14, 2016 | clinicaltrials |
| NCT00674973 | A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 207 | Hoffmann-La RocheINDUSTRY | 19 | Jun 17, 2016 | clinicaltrials |
| NCT00327171 | Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer | completed | Phase 2 | 218 | SanofiINDUSTRY | 11 | Jun 7, 2016 | clinicaltrials |
| NCT00851084 | Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer(AFFIRM) | completed | Phase 2 | 268 | SanofiINDUSTRY | 7 | Jun 7, 2016 | clinicaltrials |
| NCT01666977 | Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AmgenINDUSTRY | 6 | Jun 3, 2016 | clinicaltrials |
| NCT00259064 | Iressa v BSC (Best Supportive Care) in First Line NSCLC(INSTEP) | completed | Phase 2 / Phase 3 | 216 | AstraZenecaINDUSTRY | 5 | Jun 2, 2016 | clinicaltrials |
| NCT01088984 | Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 / Phase 2 | 43 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 12 | May 23, 2016 | clinicaltrials |
| NCT00518011 | A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer. | completed | Phase 2 | 17 | Hoffmann-La RocheINDUSTRY | 1 | May 16, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials